Australia markets close in 2 hours 34 minutes

AVXL Jan 2026 3.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
1.00000.0000 (0.00%)
As of 03:30PM EDT. Market open.
Full screen
Previous close1.0000
Open1.0000
Bid0.6500
Ask1.0000
Strike3.00
Expiry date2026-01-16
Day's range1.0000 - 1.0000
Contract rangeN/A
Volume1
Open interest2
  • GlobeNewswire

    Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024

    Webcast and Conference Call To be Held Thursday, May 9th, 2024, 8:30 am ETNEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced that it will

  • GlobeNewswire

    Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference

    NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced that it will present at the Noble Capital Markets Virtual Healthcare Equity Conferen

  • GlobeNewswire

    Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

    NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced that it will present at the 23rd Annual Needham Virtual Healthcare Conference, April